ADV联合LMV治疗LMV耐药慢性乙型肝炎临床疗效

目的观察ADV联合LMV治疗LMV耐药慢性乙型肝炎临床疗效和安全性。方法选择YMDD变异株患者68例，随机分为对照组（A组、34例）和治疗组（B组、34例），对照组继续予拉米夫定100ms／a口服治疗、治疗组联合ADVIOmg／dVI服治疗，疗程6月。检测肝、肾功能、HBVDNA，HB—sAg，治疗过程中的病情变化和不良事件的发生率。结果B组在第6月时，ALT、HBVDNA水平下降明显，与A组比较有显著性差异（P〈0．05）；A组与B组比较，ALT复常率有显著性统计学差异（P〈0．05），HBVDNA转阴率比较无显著性差异（P〉0．05），在使用ADV联合LMV治疗过程中，监测肾功能均在正常范围内，未发现明显的毒副作用。结论ADV联合LMV治疗LMV耐药慢性乙型肝炎患者具有良好的疗效和安全性。

ADV and LMV effect on the Chronic Hepatitis Patients with Hepatitis B Virus LAM-resistant

Objective To explore the efficacy and safety of ADV and LMV effect on the chronic hepa-titis patients with Hepatitis B Virus LAM-resistant. Methods The ro11 ed 68 chronic hepatitis patients with Hepatitis B Virus LAM-resistant were randomly divided into two groups:The control group( A group,34 cases) and the treatment group( group B ,34 cases), The patients in control group received lamivudineat therapy at a dose of 100 mg daily;however the patients in treatment group received lamivudineat 100 mg daily and adefovir 10 mg daily therapy, and the course of treatment was 3 months. To detect Liver and Kidney function, HBV DNA, HBsAg, and to observe the change pathogenetic condition and side effect. Results After 3 months, the treatment group's ALT and HBV DNA level decreased, Which were lower than that of group A (P<0.05), The ALT level came down to mormal in the treatment group was biger than that of group A(P<0.05). and HBV DNA level be-tween two groups was inverse. Conclusion ADV and LMV is effective and safe for the chronic hepatitis patients with Hepatitis B Virus LAM-resistant.